175 related articles for article (PubMed ID: 30612514)
21. Adaptive extensions of a two-stage group sequential procedure for testing primary and secondary endpoints (II): sample size re-estimation.
Tamhane AC; Wu Y; Mehta CR
Stat Med; 2012 Aug; 31(19):2041-54. PubMed ID: 22733687
[TBL] [Abstract][Full Text] [Related]
22. Propensity score matched augmented controls in randomized clinical trials: A case study.
Lin J; Gamalo-Siebers M; Tiwari R
Pharm Stat; 2018 Sep; 17(5):629-647. PubMed ID: 30066459
[TBL] [Abstract][Full Text] [Related]
23. Treatment effect estimation using the propensity score in clinical trials with historical control.
Kanamori S; Takeuchi M
BMC Med Res Methodol; 2024 Feb; 24(1):47. PubMed ID: 38389058
[TBL] [Abstract][Full Text] [Related]
24. Adaptive adjustment of the randomization ratio using historical control data.
Hobbs BP; Carlin BP; Sargent DJ
Clin Trials; 2013; 10(3):430-40. PubMed ID: 23690095
[TBL] [Abstract][Full Text] [Related]
25. The inclusion of historical control data may reduce the power of a confirmatory study.
Cuffe RL
Stat Med; 2011 May; 30(12):1329-38. PubMed ID: 21432893
[TBL] [Abstract][Full Text] [Related]
26. Propensity-score-based priors for Bayesian augmented control design.
Lin J; Gamalo-Siebers M; Tiwari R
Pharm Stat; 2019 Mar; 18(2):223-238. PubMed ID: 30537087
[TBL] [Abstract][Full Text] [Related]
27. Repeated randomization and matching in multi-arm trials.
Xu Z; Kalbfleisch JD
Biometrics; 2013 Dec; 69(4):949-59. PubMed ID: 24134592
[TBL] [Abstract][Full Text] [Related]
28. Propensity score-integrated Bayesian prior approaches for augmented control designs: a simulation study.
Wang X; Suttner L; Jemielita T; Li X
J Biopharm Stat; 2022 Jan; 32(1):170-190. PubMed ID: 34939894
[TBL] [Abstract][Full Text] [Related]
29. Designing historical control studies with survival endpoints using exact statistical inference.
Han G
Pharm Stat; 2021 Jan; 20(1):4-14. PubMed ID: 32743949
[TBL] [Abstract][Full Text] [Related]
30. Curtailed two-stage design for comparing two arms in randomized phase II clinical trials.
Chen CM; Chi Y; Chang HM
J Biopharm Stat; 2018; 28(5):939-950. PubMed ID: 29355457
[TBL] [Abstract][Full Text] [Related]
31. Testing for positive control activity in a thorough QTc study.
Zhang J
J Biopharm Stat; 2008; 18(3):517-28. PubMed ID: 18470760
[TBL] [Abstract][Full Text] [Related]
32. Assurance for clinical trial design with normally distributed outcomes: Eliciting uncertainty about variances.
Alhussain ZA; Oakley JE
Pharm Stat; 2020 Nov; 19(6):827-839. PubMed ID: 32537910
[TBL] [Abstract][Full Text] [Related]
33. Sample size calculation and blinded recalculation for analysis of covariance models with multiple random covariates.
Zimmermann G; Kieser M; Bathke AC
J Biopharm Stat; 2020; 30(1):143-159. PubMed ID: 31327284
[TBL] [Abstract][Full Text] [Related]
34. Robust meta-analytic-predictive priors in clinical trials with historical control information.
Schmidli H; Gsteiger S; Roychoudhury S; O'Hagan A; Spiegelhalter D; Neuenschwander B
Biometrics; 2014 Dec; 70(4):1023-32. PubMed ID: 25355546
[TBL] [Abstract][Full Text] [Related]
35. A behavioural Bayes approach to the determination of sample size for clinical trials considering efficacy and safety: imbalanced sample size in treatment groups.
Kikuchi T; Gittins J
Stat Methods Med Res; 2011 Aug; 20(4):389-400. PubMed ID: 20223784
[TBL] [Abstract][Full Text] [Related]
36. Two-stage designs for cross-over bioequivalence trials.
Kieser M; Rauch G
Stat Med; 2015 Jul; 34(16):2403-16. PubMed ID: 25809815
[TBL] [Abstract][Full Text] [Related]
37. Summarizing historical information on controls in clinical trials.
Neuenschwander B; Capkun-Niggli G; Branson M; Spiegelhalter DJ
Clin Trials; 2010 Feb; 7(1):5-18. PubMed ID: 20156954
[TBL] [Abstract][Full Text] [Related]
38. Utilizing shared internal control arms and historical information in small-sized platform clinical trials.
Jiao F; Tu W; Jimenez S; Crentsil V; Chen YF
J Biopharm Stat; 2019; 29(5):845-859. PubMed ID: 31462131
[TBL] [Abstract][Full Text] [Related]
39. Modified power prior with multiple historical trials for binary endpoints.
Banbeta A; van Rosmalen J; Dejardin D; Lesaffre E
Stat Med; 2019 Mar; 38(7):1147-1169. PubMed ID: 30360016
[TBL] [Abstract][Full Text] [Related]
40. Group Sequential Design for Randomized Phase III Trials under the Weibull Model.
Wu J; Xiong X
J Biopharm Stat; 2015; 25(6):1190-205. PubMed ID: 25322440
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
